Meldoxon (Meldonium Dihydrate)

Meldonium inhibits the enzyme gamma‑butyrobetaine hydroxylase, reducing the synthesis of carnitine. Lower carnitine levels decrease fatty‑acid oxidation in heart muscle cells and promote glucose oxidation, a more oxygen‑efficient energy pathway. This metabolic shift enhances cardiac performance during ischemic conditions.

The specific dose and infusion rate of Meldoxon are determined by the prescribing physician based on the individual patient's clinical condition, severity of disease, and response to therapy. Healthcare professionals adjust the regimen according to established guidelines and patient monitoring.

Safety data for Meldoxon in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Clinicians must evaluate each case individually and discuss potential risks with the patient.

To request Meldoxon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Unlike traditional vasodilators or beta‑blockers, Meldoxon acts as a metabolic modulator, targeting myocardial energy pathways rather than directly influencing heart rate or vascular tone. This mechanism can complement other therapies, offering a distinct approach for patients with ischemic heart conditions where oxygen efficiency is a priority.

Meldoxon should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Do not store at room temperature for extended periods.

Meldoxon is given intravenously by a healthcare professional. The solution is infused over a prescribed period, typically under continuous monitoring of cardiac function and vital signs to ensure safety and therapeutic effectiveness.

Serious adverse reactions to Meldoxon can include severe allergic responses such as anaphylaxis, cardiac arrhythmias, significant hepatic dysfunction, and acute renal injury. Prompt recognition and medical intervention are essential if any of these events occur.

Meldoxon is contraindicated in patients with known hypersensitivity to meldonium or any excipients in the formulation. It should also be avoided in individuals receiving monoamine oxidase inhibitors or those with uncontrolled severe hypertension, unless a physician determines that benefits outweigh risks.